Interessante a explicação do especialista do Realmoney em Biotechs sobre a queda abrupta antes da suspensão...
Adam Feuerstein
ImClone Tanks Before Erbitux Approval
2/13/04 8:43 AM ET
"So, what's the real story behind the freefall in ImClone (IMCL:Nasdaq) shares just prior to Thursday's FDA approval of Erbitux? I can't profess to know for sure, but I heard a doozy of an explanation last night. It sure sounds plausible, although rather impossible to verify, so we'll just call it a story for now. Here's how it goes:
There was supposedly a leak. A hedge fund was allegedly tipped off to the moment when the FDA letter arrived at ImClone's New York office on Thursday. This hedge fund wasn't privy to the content of the FDA letter, but when a significant amount of time passed without a triumphant ImClone news release crossing the wires, this hedgie apparently figured that the FDA letter brought bad news and that ImClone management was trying to figure out how to deal with it.
So, this hedge fund supposedly made a bet and started selling his ImClone shares, which started the stock rolling downhill. Rumors spread and the pace of selling picked up as stop-loss orders were tripped. Boom! In a blink of an eye, ImClone is down $9 and change and the stock is halted.
Well, if true, this guy made the wrong bet. ImClone, mindful of its checkered history with the FDA, decided not to write a complete Erbitux press release in advance. The company wanted to wait to see the actual FDA letter before finishing its release. This took time, which explains the delay in getting the news release onto the wires and why the FDA's own announcement about the Erbitux approval was released first.
The rest, as we know, is history and somehow completely fitting to the ImClone legend. A plain vanilla Erbitux approval would have been boring, don't you think? "
(in
www.realmoney.com)